NovoCure Aktie

14,94 EUR -0,47 EUR -3,05 %

04.04.2025

STU

16,48 USD -0,51 USD -3,00 %

nachbörslich04.04.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.1,65 Mrd. EUR

Div. Rendite0,00%

WKNA140ML

ISINJE00BYSS4X48

SymbolNVCR

NovoCure Aktien News

Sortieren:Datum Meistgelesen

04.06.24BenzingaA Closer Look at 7 Analyst Recommendations For NovoCure

03.06.24BusinesswireMETIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

03.05.24MotleyFoolNovoCure (NVCR) Q1 2024 Earnings Call Transcript

02.05.24BenzingaUnveiling 8 Analyst Insights On NovoCure

02.05.24ZacksNovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

02.05.24BusinesswireNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

02.05.24BusinesswireNovocure Reports First Quarter 2024 Financial Results

25.04.24ZacksNovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?

01.04.24BusinesswireNovocure to Report First Quarter 2024 Financial Results

11.03.24BusinesswireINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

22.02.24BusinesswireNovocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

18.01.24BusinesswireNovocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

09.01.24BusinesswireNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

08.01.24BusinesswireNovocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

04.01.24BusinesswireNovocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

27.12.23BusinesswireNovocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

28.11.23BusinesswireNovocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

21.11.23BusinesswireNovocure to Participate in 35th Annual Piper Sandler Healthcare Conference

10.11.23BusinesswireNovocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

26.10.23BusinesswireNovocure Reports Third Quarter 2023 Financial Results

16.10.23BusinesswireNovocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

12.10.23BusinesswireNovocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

29.09.23BusinesswireNovocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

08.09.23BusinesswireNovocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

30.08.23BusinesswireNovocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

28.08.23BusinesswireNovocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer

25.08.23BusinesswireNovocure to Participate in Upcoming Investor Conferences

15.08.23PR NewswireNVCR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 18, 2023 in the Class Action Filed on Behalf of NovoCure Limited Shareholders

11.08.23PR NewswireNVCR Investors Have Opportunity to Lead NovoCure Limited Securities Fraud Lawsuit

10.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

10.08.23PR NewswireNVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

10.08.23PR NewswireNVCR DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important August 18 Deadline in Securities Class Action - NVCR

04.08.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

02.08.23PR NewswireSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 - (NASDAQ: NVCR)

27.07.23BusinesswireNovocure Reports Second Quarter 2023 Financial Results

21.07.23BusinesswireNovocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

17.07.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

13.07.23PR NewswireNVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

12.07.23PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

08.07.23PR NewswireROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR

NovoCure News

NovoCure News: auf dieser Seite finden Sie alle NovoCure News und Nachrichten zur NovoCure Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch NovoCure News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um NovoCure News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.